195 related articles for article (PubMed ID: 12511418)
21. A study of the mechanism of action of pyridoxal isonicotinoyl hydrazone at the cellular level using reticulocytes loaded with non-heme 59Fe.
Huang AR; Ponka P
Biochim Biophys Acta; 1983 Jun; 757(3):306-15. PubMed ID: 6849979
[TBL] [Abstract][Full Text] [Related]
22. Effect of pyridoxal isonicotinoyl hydrazone and analogs on iron metabolism in hepatocytes and macrophages in culture.
Richardson D; Baker E; Ponka P; Wilairat P; Vitolo ML; Webb J
Birth Defects Orig Artic Ser; 1988; 23(5B):81-8. PubMed ID: 3390577
[No Abstract] [Full Text] [Related]
23. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture.
Hershko C; Konijn AM; Nick HP; Breuer W; Cabantchik ZI; Link G
Blood; 2001 Feb; 97(4):1115-22. PubMed ID: 11159545
[TBL] [Abstract][Full Text] [Related]
24. The effect of various chelating agents on the mobilization of iron from reticulocytes in the presence and absence of pyridoxal isonicotinoyl hydrazone.
Ponka P; Grady RW; Wilczynska A; Schulman HM
Biochim Biophys Acta; 1984 Dec; 802(3):477-89. PubMed ID: 6509088
[TBL] [Abstract][Full Text] [Related]
25. Effects of chelators on iron uptake and release by the brain in the rat.
Crowe A; Morgan EH
Neurochem Res; 1994 Jan; 19(1):71-6. PubMed ID: 8139766
[TBL] [Abstract][Full Text] [Related]
26. Cytotoxic analogs of the iron(III) chelator pyridoxal isonicotinoyl hydrazone: effects of complexation with copper(II), gallium(III), and iron (III) on their antiproliferative activities.
Richardson DR
Antimicrob Agents Chemother; 1997 Sep; 41(9):2061-3. PubMed ID: 9303419
[TBL] [Abstract][Full Text] [Related]
27. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
Chaston TB; Lovejoy DB; Watts RN; Richardson DR
Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
[TBL] [Abstract][Full Text] [Related]
28. The iron chelator pyridoxal isonicotinoyl hydrazone (PIH) protects plasmid pUC-18 DNA against *OH-mediated strand breaks.
Hermes-Lima M; Nagy E; Ponka P; Schulman HM
Free Radic Biol Med; 1998 Nov; 25(8):875-80. PubMed ID: 9840731
[TBL] [Abstract][Full Text] [Related]
29. Pyridoxal isonicotinoyl hydrazone (PIH): a promising new iron chelator.
Webb J; Vitolo ML
Birth Defects Orig Artic Ser; 1988; 23(5B):63-70. PubMed ID: 3291971
[No Abstract] [Full Text] [Related]
30. Objectives and mechanism of iron chelation therapy.
Hershko C; Link G; Konijn AM; Cabantchik ZI
Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
[TBL] [Abstract][Full Text] [Related]
31. Chemical studies of pyridoxal isonicotinoyl hydrazone relevant to its clinical evaluation.
Vitolo ML; Clare BW; Hefter GT; Webb J
Birth Defects Orig Artic Ser; 1988; 23(5B):71-9. PubMed ID: 3390576
[No Abstract] [Full Text] [Related]
32. An in vivo evaluation of iron-chelating drugs derived from pyridoxal and its analogs.
Johnson DK; Pippard MJ; Murphy TB; Rose NJ
J Pharmacol Exp Ther; 1982 May; 221(2):399-403. PubMed ID: 7077535
[TBL] [Abstract][Full Text] [Related]
33. Iron chelation therapy.
Hershko CM; Link GM; Konijn AM; Cabantchik ZI
Curr Hematol Rep; 2005 Mar; 4(2):110-6. PubMed ID: 15720959
[TBL] [Abstract][Full Text] [Related]
34. Oxidative stress mediates toxicity of pyridoxal isonicotinoyl hydrazone analogs.
Buss JL; Neuzil J; Ponka P
Arch Biochem Biophys; 2004 Jan; 421(1):1-9. PubMed ID: 14678779
[TBL] [Abstract][Full Text] [Related]
35. Pyridoxal isonicotinoyl hydrazone (PIH) prevents copper-mediated in vitro free radical formation.
Hermes-Lima M; Gonçalves MS; Andrade RG
Mol Cell Biochem; 2001 Dec; 228(1-2):73-82. PubMed ID: 11855743
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of oral iron chelators assayed in the rat.
Kim BK; Huebers HA; Finch CA
Am J Hematol; 1987 Mar; 24(3):277-84. PubMed ID: 3826055
[TBL] [Abstract][Full Text] [Related]
37. Hydrolysis of pyridoxal isonicotinoyl hydrazone and its analogs.
Buss JL; Ponka P
Biochim Biophys Acta; 2003 Jan; 1619(2):177-86. PubMed ID: 12527114
[TBL] [Abstract][Full Text] [Related]
38. Pyridoxal Isonicotinoyl Hydrazone Improves Neurological Recovery by Attenuating Ferroptosis and Inflammation in Cerebral Hemorrhagic Mice.
Zhang H; Wen M; Chen J; Yao C; Lin X; Lin Z; Ru J; Zhuge Q; Yang S
Biomed Res Int; 2021; 2021():9916328. PubMed ID: 34541001
[TBL] [Abstract][Full Text] [Related]
39. Orally effective iron chelators for the treatment of iron overload disease: the case for a further look at pyridoxal isonicotinoyl hydrazone and its analogs.
Richardson DR; Ponka P
J Lab Clin Med; 1998 Oct; 132(4):351-2. PubMed ID: 9794707
[No Abstract] [Full Text] [Related]
40. Aging-related changes in the iron status of skeletal muscle.
DeRuisseau KC; Park YM; DeRuisseau LR; Cowley PM; Fazen CH; Doyle RP
Exp Gerontol; 2013 Nov; 48(11):1294-302. PubMed ID: 23994517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
